within Pharmacolibrary.Drugs.ATC.M;

model M04AX02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016166666666666665,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0045,
    k12             = 8.6,
    k21             = 8.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M04AX02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pegloticase is a recombinant uricase enzyme conjugated to polyethylene glycol, used in the treatment of chronic gout refractory to conventional therapy. It enzymatically catalyzes the oxidation of uric acid to allantoin, which is more soluble and easily excreted. Pegloticase is approved for use in adults with severe, treatment-refractory chronic gout.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with chronic gout after intravenous infusion every 2 weeks.</p><h4>References</h4><ol><li><p>Bleyer, AJ, et al., &amp; Alcorn, H (2015). Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis. <i>Clinical nephrology</i> 83(5) 286–292. DOI:<a href=&quot;https://doi.org/10.5414/CN108481&quot;>10.5414/CN108481</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25816806/&quot;>https://pubmed.ncbi.nlm.nih.gov/25816806</a></p></li><li><p>Shannon, JA, &amp; Cole, SW (2012). Pegloticase: a novel agent for treatment-refractory gout. <i>The Annals of pharmacotherapy</i> 46(3) 368–376. DOI:<a href=&quot;https://doi.org/10.1345/aph.1Q593&quot;>10.1345/aph.1Q593</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22395256/&quot;>https://pubmed.ncbi.nlm.nih.gov/22395256</a></p></li><li><p>Biggers, K, &amp; Scheinfeld, N (2008). Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. <i>Current opinion in investigational drugs (London, England : 2000)</i> 9(4) 422–429. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18393109/&quot;>https://pubmed.ncbi.nlm.nih.gov/18393109</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M04AX02;
